Methods and treatments for the learning and memory deficits associated with Noonan syndrome

Patent metadata

Field	Value
Publication number	US-10835513-B2
Application number	US-201414900907-A
Country	US
Kind code	B2
Filing date	Jun 27, 2014
Priority date	Jun 28, 2013
Publication date	Nov 17, 2020
Grant date	Nov 17, 2020

Abstract

Disclosed herein are methods and compositions for treating learning and memory deficits associated with Noonan Syndrome.

First claim

What is claimed is:

1. A method of treating a cognitive deficit in a subject having Noonan syndrome, comprising:
administering an effective amount of one or more hydroxymethylglutaryl CoA (HMG CoA) reductase inhibitors to a subject having the cognitive deficit and Noonan syndrome.

2. The method of claim 1 , wherein the one or more HMG CoA inhibitors comprises a statin.

3. The method of claim 2 , wherein the statin is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, pitavastatin, rovustatin, simvastatin, and mixtures thereof.

4. The method according to claim 1 , wherein the effective amount does not significantly lower total serum cholesterol level in the subject.

5. The method according to claim 1 , which further comprises administering a farnesyl transferase inhibitor, a geranylgeranyl transferase inhibitor, an inhibitor of γ-aminobutyric acid (GABA) mediated inhibition, an inhibitor of GABA receptor activity, and/or a modulator of Ras-ERK signaling.

6. The method according to claim 1 , wherein the supplementary compound is administered before, during, and/or after the inhibitor.

7. The method according to claim 1 , wherein the administering is by adjunctive administration.

8. The method of claim 7 , wherein the adjunctive administration is simultaneous administration.

9. The method of claim 7 , wherein the adjunctive administration is sequential administration.

10. The method of claim 1 , wherein said subject has a normal cholesterol level.

11. The method of claim 1 , which further comprises administering an effective amount of an inhibitor of MEK to the subject.

12. The method of claim 11 , wherein the inhibitor of MEK is a specific inhibitor of MEK1 and/or MEK2.

13. The method of claim 11 , wherein the inhibitor of MEK is α-(Amino((4-aminophenyl)thio)methylene)-2-(trifluoromethyl)benzeneacetonitrile (SL327).

14. The method of claim 11 , wherein the one or more hydroxymethylglutaryl CoA (HMG CoA) reductase inhibitors are administered before, during, and/or after administration of the inhibitor of MEK.

15. A method of improving cognitive function of a subject having a cognitive deficit and Noonan syndrome, comprising:
administering an effective amount of one or more hydroxymethylglutaryl CoA (HMG CoA) reductase inhibitors to a subject having the cognitive deficit and Noonan syndrome.

Assignees

• Univ California

Inventors

• Silva Alcino
• Lee Yong-Seok
• Ehninger Dan

Classifications

• A61K31/22

  of acyclic acids, e.g. pravastatin · CPC title

• A61K31/505

  Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim · CPC title

• A61K31/404

  Indoles, e.g. pindolol · CPC title

• A61K31/40

  having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil · CPC title

• A61K31/277

  having a ring, e.g. verapamil · CPC title